Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.

Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.
Bull Cancer. 2018 Oct 13;:
Authors: Cohen R, Pellat A, Boussion H, Svrcek M, Lopez-Trabada D, Trouilloud I, Afchain P, André T
Abstract
Microsatellite instability (MSI) is a molecular indicator of defective DNA mismatch repair (dMMR) and is observed in approximately 5% of metastatic colorectal cancers (mCRC). MSI is a major predictive biomarker for the efficacy of immune checkpoint inhibitors (ICKi) amongst mCRC patients. After summarizing the literature about the efficacy of conventional cytotoxic regimens, we will highlight studies that have demonstrated the clinical activity of ICKi for patients with chemoresistant MSI/dMMR mCRC. Then we will focus on ongoing clinical trials and emerging challenges for the treatment of patients with MSI/dMMR mCRC.
PMID: 30327191 [PubMed - as supplied by publisher]

Source: Bulletin du Cancer - October 13, 2018 Category: Cancer & Oncology Authors: Cohen R, Pellat A, Boussion H, Svrcek M, Lopez-Trabada D, Trouilloud I, Afchain P, André T Tags: Bull Cancer Source Type: research